6/2/2005 11:49:38 AM ET


    SWISS MEDICA AND NATIONAL FIBROMYALGIA ASSOCIATION SCHEDULE JOINT ANNOUNCEMENT OF NEW
    BREAKTHROUGH PAIN RELIEF TREATMENT FOR FIBROMYALGIA SUFFERERS
      
    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB: SWME
    June 2, 2005

    SWISS MEDICA AND NATIONAL FIBROMYALGIA ASSOCIATION SCHEDULE JOINT ANNOUNCEMENT OF NEW
    BREAKTHROUGH PAIN RELIEF TREATMENT FOR FIBROMYALGIA SUFFERERS

    Toronto, Canada – Swiss Medica Inc. (OTC BB: SWME) will host a joint press announcement with the National
    Fibromyalgia Association (NFA) on June 6, 2005 at the National Association of Chain Drug Stores (NACDS)
    Marketplace conference in New Orleans to unveil a new strategic partnership – and officially launch O24™
    Fibromyalgia pain reliever. O24™ Fibromyalgia is the first product of its kind developed to specifically address
    the symptoms of chronic pain associated with the fibromyalgia syndrome and is also a patented and clinically
    tested, strong and safe, all-natural, over-the-counter health product. Swiss Medica is the owner and distributor
    of this product.

    Lynne Matallana, the founder and president of the NFA, will speak at a press conference about the plight of up
    to 11 million Americans living with the chronic pain caused by fibromyalgia – and how Swiss Medica’s new O24™
    Fibromyalgia pain reliever will become the first product to carry the NFA official Seal of Approval on its
    packaging. Swiss Medica President, Grant Johnson will discuss the previously announced results of a recently
    completed randomized double blind clinical trial that compared the O24™ pain reliever against a placebo on
    patients suffering fibromyalgia.

    Fibromyalgia is typically characterized by widespread musculoskeletal aches, pain and stiffness, soft tissue
    tenderness, general fatigue and sleep disturbances. The most common sites of pain include the neck, back,
    shoulders, pelvic girdle and hands. Fibromyalgia patients experience a range of symptoms, varying in intensity
    that can fluctuate over time.

    The NFA estimates that the average family doctor sees at least one patient each day who is suffering from
    fibromyalgia and that the syndrome could be costing the U.S. economy as much as $10 billion a year in lost
    productivity.

    Ms. Matallana and Mr. Johnson will also discuss the launch of the new O24™ Fibromyalgia product in
    pharmacies throughout the United States and Canada. Swiss Medica’s O24™ Pain Neutralizer will be available in
    over 13,000 stores throughout North America by the end of June 2005.

    About the National Fibromyalgia Association

    The National Fibromyalgia Association (previously known as the National Fibromyalgia Awareness Campaign) is
    a [501(c) 3] nonprofit organization whose mission is: To develop and execute programs dedicated to improving
    the quality of life for people with Fibromyalgia by increasing the awareness of the public, media, government and
    medical communities. The NFA is committed to efforts that will increase FM awareness and improve treatment
    options for people with Fibromyalgia. With teamwork and dedication, the NFA will continue to grow into a key
    organization helping people with FM everywhere.

    About Swiss Medica Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be
    a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

    Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
    relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
    healthcare professionals in the United States, Canada and in Europe. O24™ is widely available throughout
    Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of
    pharmacies throughout the United States. Customers can also visit www.O24zone.com, for ordering details and
    store locators for the nearest pharmacy.

    Swiss Medica also manufactures PMS Escape® which holds US Patent #’s 5760014 and 5612320. PMS
    Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
    changes in mood and appetite that women experience during the premenstrual period. Customers can also visit
    www.pmsescape.com for additional information and ordering details.


    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
    United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    For more information, please contact:

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    djones@swissmedica.com